Cerebrospinal fluid human chorionic gonadotropin levels in normal pregnancy and choriocarcinoma.
We measured human chorionic gonadotropin levels simultaneously in the serum and cerebrospinal fluid of 36 normal pregnant women and of six patients with choriocarcinoma. During normal pregnancy, human chorionic gonadotropin levels in the cerebral spinal fluid correlated well with those in the serum in both the first and third trimesters. A serum-cerebral spinal fluid human chorionic gonadotropin ratio of less than 60 has previously been reported as a sensitive diagnostic test for trophoblastic central nervous system involvement. However, we found this ratio to be less than 60 in one patient undergoing first trimester abortion and in one patient with nonmetastatic choriocarcinoma. Furthermore, two patients with documented trophoblastic cerebral metastases had serum-cerebral spinal fluid human chorionic gonadotropin ratios in excess of 60. Results of our study, thus, indicate that determination of a single serum-cerebral spinal fluid human chorionic gonadotropin ratio may not conclusively prove or exclude trophoblastic central nervous system metastases. Unless it is corroborated by other diagnostic means, a single decreased serum-cerebral spinal fluid human chorionic gonadotropin ratio is insufficient evidence to initiate multimodality treatment for presumptive central nervous system involvement.
D001932:Brain Neoplasms / Q000134:cerebrospinal fluid / Q000556:secondary; D002822:Choriocarcinoma / Q000134:cerebrospinal fluid* / Q000556:secondary; D006063:Chorionic Gonadotropin / Q000097:blood / Q000134:cerebrospinal fluid*; D005260:Female; D006801:Humans; D011247:Pregnancy; D011248:Pregnancy Complications; D014594:Uterine Neoplasms / Q000134:cerebrospinal fluid*
D006063:Chorionic Gonadotropin